These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22317769)

  • 1. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors.
    Strosberg JR; Weber JM; Choi J; Campos TL; Valone TL; Han G; Schell MJ; Kvols LK
    Ann Oncol; 2012 Sep; 23(9):2335-2341. PubMed ID: 22317769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy.
    del Puerto-Nevado L; Rojo F; Zazo S; Caramés C; Rubio G; Vega R; Chamizo C; Casado V; Martínez-Useros J; Rincón R; Rodríguez-Remírez M; Borrero-Palacios A; Cristóbal I; Madoz-Gúrpide J; Aguilera O; García-Foncillas J
    Br J Cancer; 2014 May; 110(11):2700-7. PubMed ID: 24786599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.
    Harmon CS; DePrimo SE; Raymond E; Cheng AL; Boucher E; Douillard JY; Lim HY; Kim JS; Lechuga MJ; Lanzalone S; Lin X; Faivre S
    J Transl Med; 2011 Jul; 9():120. PubMed ID: 21787417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
    Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
    Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib.
    Thian Y; Gutzeit A; Koh DM; Fisher R; Lote H; Larkin J; Sohaib A
    Radiology; 2014 Nov; 273(2):452-61. PubMed ID: 24869795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.
    Stubbs C; Bardoli AD; Afshar M; Pirrie S; Miscoria M; Wheeley I; Porfiri E
    Anticancer Res; 2017 Jan; 37(1):253-259. PubMed ID: 28011500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic artery embolization for liver metastasis of gastrointestinal stromal tumor following imatinib and sunitinib therapy.
    Takaki H; Litchman T; Covey A; Cornelis F; Maybody M; Getrajdman GI; Sofocleous CT; Brown KT; Solomon SB; Alago W; Erinjeri JP
    J Gastrointest Cancer; 2014 Dec; 45(4):494-9. PubMed ID: 25358551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
    Xie M; He CS; Huang JK; Lin QZ
    Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers.
    Kontovinis LF; Papazisis KT; Touplikioti P; Andreadis C; Mouratidou D; Kortsaris AH
    BMC Cancer; 2009 Mar; 9():82. PubMed ID: 19284623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
    Hutson TE; Escudier B; Esteban E; Bjarnason GA; Lim HY; Pittman KB; Senico P; Niethammer A; Lu DR; Hariharan S; Motzer RJ
    J Clin Oncol; 2014 Mar; 32(8):760-7. PubMed ID: 24297950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.
    Heng DY; Mackenzie MJ; Vaishampayan UN; Bjarnason GA; Knox JJ; Tan MH; Wood L; Wang Y; Kollmannsberger C; North S; Donskov F; Rini BI; Choueiri TK
    Ann Oncol; 2012 Jun; 23(6):1549-55. PubMed ID: 22056973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma.
    Izzedine H; Derosa L; Le Teuff G; Albiges L; Escudier B
    Ann Oncol; 2015 Jun; 26(6):1128-1133. PubMed ID: 25795198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
    Rini BI; Cohen DP; Lu DR; Chen I; Hariharan S; Gore ME; Figlin RA; Baum MS; Motzer RJ
    J Natl Cancer Inst; 2011 May; 103(9):763-73. PubMed ID: 21527770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma.
    Beuselinck B; Verbiest A; Couchy G; Job S; de Reynies A; Meiller C; Albersen M; Verkarre V; Lerut E; Méjean A; Patard JJ; Laguerre B; Rioux-Leclercq N; Schöffski P; Oudard S; Zucman-Rossi J
    Acta Oncol; 2018 Apr; 57(4):498-508. PubMed ID: 29095068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.
    Scartozzi M; Bianconi M; Faloppi L; Loretelli C; Bittoni A; Del Prete M; Giampieri R; Maccaroni E; Nicoletti S; Burattini L; Minardi D; Muzzonigro G; Montironi R; Cascinu S
    Br J Cancer; 2013 Mar; 108(5):1126-32. PubMed ID: 23511629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
    Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P
    N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.
    Liu G; Jeraj R; Vanderhoek M; Perlman S; Kolesar J; Harrison M; Simoncic U; Eickhoff J; Carmichael L; Chao B; Marnocha R; Ivy P; Wilding G
    Clin Cancer Res; 2011 Dec; 17(24):7634-44. PubMed ID: 22038997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Regulatory T Cells: A Novel Marker Associated with Liver Metastasis and the Treatment Response of Transarterial Embolization in Gastroenteropancreatic Neuroendocrine Tumors.
    Liu M; Yu H; Chen L; Yang D; Liu H; Ouyang J; Zhang J; Yan X; Luo Y; Lin Y; He Q; Chen M; Zhang N; Wang Y
    Neuroendocrinology; 2024; 114(9):827-839. PubMed ID: 38061350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.